Is Berberine Safe? Why We’re Not Selling “Nature’s Ozempic”

Key takeaways

•    Berberine is a plant compound marketed heavily on social media as “nature’s Ozempic,” a natural alternative to GLP-1 weight loss injections.

•    Much of that marketing is aimed at women, and it arrived alongside a wider cultural shift that has put renewed pressure on people to shrink.

•    The evidence for weight loss is modest. Berberine’s clearest research is around blood sugar, and even there the studies are often small and short.

•    In January 2026, the European Food Safety Authority published a draft opinion concluding it could not establish a safe intake level for berberine-containing plant preparations, citing concerns including genotoxicity and liver injury.

•    Metabolics does not sell berberine. We are waiting for the safety science to settle, because a supplement should earn its place through evidence, not virality.

 

If you spend any time on TikTok or Instagram, you have probably met berberine already. It is the bright yellow capsule held up to the camera, the “hack” nobody is supposed to know about, the supplement an influencer swears changed everything. For the past couple of years it has carried a nickname that did most of the selling for it: “nature’s Ozempic.”

We get asked about it a lot. Customers, and sometimes practitioners, want to know why a company with over 250 products and several forms of magnesium does not offer the single most talked-about supplement of the moment. It would be easy to add one. The honest answer is that we are waiting for the science, and the reasons why are worth explaining properly, because they say something about how the whole trend has been sold.

Berberine is not new. It is a compound found in plants such as barberry, goldenseal and Oregon grape, and it has been used in traditional Chinese and Ayurvedic medicine for centuries, mostly for digestive complaints (CBC News). What is new is the marketing.

The nickname borrows its power from a genuine pharmaceutical story. GLP-1 medicines such as Ozempic, Wegovy and Mounjaro produce significant, medically supervised weight loss, and demand for them has been extraordinary. That demand created shortages and, for many people, a wall of cost, with branded injections running to hundreds of pounds a month (CBC News). Into that gap stepped a cheaper, over-the-counter option that anyone could buy for a few pounds, wrapped in a name that promised the same results without the prescription (MM+M). A trend was born, and it spread the way these things always do: through before-and-after photos and weekly video updates rather than through evidence.

It is worth being clear-eyed about the culture berberine landed in. The arrival of GLP-1 medicines has done more than change how some people manage their weight. It has changed the conversation around bodies altogether. Psychologists have started describing an “Ozempic effect,” a broad rise in body surveillance and social comparison as dramatic weight loss becomes more visible and, for some, more attainable (Meridian Counseling).

That pressure is not felt equally. Charlotte Markey, professor of psychology at Rutgers University, has argued that GLP-1s have intensified the expectation, particularly on women, to pursue weight loss at almost any cost, reviving a cultural fixation on thinness that the body positivity movement had spent years pushing back against (Rutgers University). Commentators have called it the “Ozempic Mother” era, and note that the thin ideal of the early 2000s has quietly returned, now delivered through a phone rather than a magazine rack (The Press Democrat).

Berberine sits neatly inside that machine. The “nature’s Ozempic” trend was driven largely by women sharing their experiences online, and the marketing followed. Alongside the prescription drugs, women are now served a steady feed of over-the-counter, “no prescription needed” pills promising to quiet food noise or deliver “summer confidence,” aimed specifically at those who do not qualify for the medicines but have been made to feel they should want the result anyway (The Press Democrat). One creator put the business model plainly: companies are profiting from women’s insecurities, and this is another version of a fad diet dressed up as something new (MM+M).

This is where we want to be honest, because it matters more than any ingredient.

Weight is rarely just about weight. For a lot of people, and disproportionately for women, the decision to try something like berberine is tangled up with years of being told their body is a problem to be solved. A supplement marketed as a shortcut does not sell a mechanism. It sells relief from that feeling. That is a powerful thing to be sold, and it is worth noticing when it is happening to you.

We are not in the business of telling anyone how to feel about their body, and we are certainly not going to sell a capsule off the back of that discomfort. Research on GLP-1s and body image has found that weight loss does not reliably improve how people feel about themselves, and that self-worth is built from a much wider set of things than body size (Healthline; Meridian Counseling). If a product only makes sense when you feel bad enough, it is not a product we want to put our name to.

Set the nickname aside and look at the evidence, and a more modest picture appears.

Berberine works mainly by activating an enzyme called AMPK, sometimes described as the cell’s fuel gauge, which nudges cells to use energy rather than store it (Njiru, 2025). Its best-supported effects are metabolic. A 2021 systematic review and meta-analysis by Guo and colleagues concluded that berberine can modestly lower blood sugar and HbA1c in people with type 2 diabetes, along with a small amount of weight loss. One 2024 randomised controlled trial reported a 21% fall in fasting plasma glucose and a 15% reduction in HbA1c over twelve weeks in people with prediabetes (NutraIngredients).

Those are real findings, and they explain why the compound is taken seriously in metabolic research. But there are important caveats that rarely make it into a fifteen-second video. The weight-loss effect is small: clinicians who have looked closely put it at a few pounds on average, a long way from the fifteen to twenty pounds often seen with the actual medication (CBS News). Many of the supportive studies are short, small, or not placebo-controlled (CBC News). And because berberine is sold as a supplement rather than a medicine, the dose, purity and potency can vary considerably from one bottle to the next, so a shopper has little guarantee they are getting what the label says (Njiru, 2025). “Nature’s Ozempic” is a brilliant piece of marketing. It is not a description of how the compound behaves.

Here is the development that matters most for us, and it is recent.

In January 2026, the European Food Safety Authority’s expert panel endorsed a draft scientific opinion on berberine-containing plant preparations and opened it for public consultation, which ran from March to May 2026 (EFSA). The review was requested by the European Commission after the French food safety agency, ANSES, raised concerns about these plants being used in supplements (GOV.UK Committee on Toxicity; ANSES).

EFSA’s conclusion was striking. Rather than setting a safe daily amount, the panel found that it could not establish a safe intake level for any of the berberine-containing preparations it assessed (NutraIngredients). The concerns it flagged included signals of genotoxicity in laboratory tests, carcinogenic activity in animal studies, and cases of idiosyncratic liver injury, set against significant gaps in the data (NutraIngredients). ANSES had separately advised caution over long-term safety, interactions with medicines, use in pregnancy and breastfeeding, and use by people with diabetes or certain liver and heart conditions (ANSES).

In plain terms, the direction of travel in Europe is toward restriction. Depending on how the process concludes, berberine could be prohibited in supplements or placed under formal scrutiny while companies are given time to fill the missing safety data (NutraIngredients). The UK’s own Committee on Toxicity has been reviewing the same draft opinion (GOV.UK Committee on Toxicity).

In fairness, not everyone agrees with EFSA’s approach. Some scientists argue that several of the concerns may relate to other compounds present in the whole-plant preparations rather than to berberine itself, and that short-term, sensible use is a different proposition from the daily, long-term animal exposures behind some of the findings (NutraIngredients). That debate is genuine, and it is exactly why we would rather wait for it to resolve than pre-empt it.

We have always preferred a conservative, evidence-led position. Before we introduce any ingredient, we review the available science and the views of independent regulators, and we ask a simple question: does the evidence support both efficacy and safety? Where the answer is not yet clear, we would rather hold back than move quickly.

Sometimes that means we are slower to a trend than others. We are comfortable with that. Our customers and the practitioners who recommend us expect us to prioritise quality, transparency and responsible decision-making over the size of our range. Choosing not to launch a product is as much a part of that standard as choosing to launch one.

Possibly. We are not closing the door. We will keep watching the literature and the guidance from EFSA, ANSES and the UK authorities, and if the safety evidence becomes reassuring and the appropriate use is clear, we will review our position openly.

Until then, the responsible decision is to leave it off our shelves. Not because berberine is proven harmful, and not because we doubt that some of the research is interesting, but because “we are still checking” is a more honest thing to tell you than “everyone else is selling it, so here you go.”

Berberine is the most visible example yet of a supplement sold on a feeling rather than on its evidence, and of a wider culture that has learned to profit from the pressure people, especially women, feel about their bodies. The science on its benefits is modest, the science on its long-term safety is unsettled, and the most credible regulator in the field has just said it cannot yet call it safe. That is reason enough for us to wait. When the evidence is ready, we will be too. Until then, we would rather be the brand that tells you the truth than the one that tells you what you want to hear.